Rafael Mejuto Fernandez

Rafael Mejuto Fernandez

Auto-generated profile, based on publicly available information

Rafael Mejuto Fernandez

Rutgers Robert Wood Johnson Medical School, Robert Wood Johnson University Hospital

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 April 2020 in Gut
Verified
Journal Article
Closed access
PDF file
EDEnrique de-Madaria
Enrique de-Madaria
CSClaudia Sánchez-Marin
Claudia Sánchez-Marin
Irene Carrillo MurciaIrene Carrillo Murcia
Irene Carrillo Murcia
SVSanthi Swaroop Vege
Santhi Swaroop Vege
SCSerge Chooklin
Serge Chooklin
JMJosé J Mira
José J Mira
Objective This study aimed to develop and validate a patient-reported outcome measure (PROM) in acute pancreatitis (AP) as an endpoint centred on the patient. Design A PROM instrument (PAtieNt-rePoRted OutcoMe scale in acute pancreatItis, an international proSpEctive cohort study, PAN-PROMISE scale) was designed based on the opinion of patients, professionals and an expert panel. The scale was validated in an international multicentre prospective cohort study, describing the severity of AP and quality of life at 15 days after discharge as the main variables for validation. The COSMIN (COnsensus-based Standards for the selection of health status Measurement INstruments) methodology was applied. Both the design and validation stages considered the content and face validity of this new instrument; the metric properties of the different items, reliability (reproducibility and internal consistence), the construct, structural and criterion validity, responsiveness and interpretability of this scale. Results PAN-PROMISE consists of a seven-item scale based on the symptoms that cause the most discomfort and concern to patients with AP. The validation cohort involved 15 countries, 524 patients. The intensity of symptoms changed from higher values during the first 24 hours to lower values at discharge and 15 days thereafter. Items converged into a unidimensional ordinal scale with good fit indices. Internal consistency and split-half reliability at discharge were adequate. Reproducibility was confirmed using test–retest reliability and comparing the PAN-PROMISE score at discharge and 15 days after discharge. Evidence is also provided for the convergent-discriminant and empirical validity of the scale. Conclusion The PAN-PROMISE scale is a useful tool to be used as an endpoint in clinical trials, and to quantify patient well-being during the hospital admission and follow-up. Trial registration number NCT03650062

19 February 2020 in Surgical Endoscopy
Verified
Journal Article
Closed access
PDF file
JLJosé Lariño-Noia
José Lariño-Noia
DGDaniel De la Gglesia garcia
Daniel De la Gglesia garcia
JGJaime Gonzalez-Lopez
Jaime Gonzalez-Lopez
JDJavier Díaz-Lopez
Javier Díaz-Lopez
FMFernando Macías-García
Fernando Macías-García
JDJ. Enrique Domínguez-Muñoz
J. Enrique Domínguez-Muñoz

30 May 2021 in Clinical Endoscopy
Verified
Journal Article
Open access
PDF file
RMRafael Mejuto-Fernandez
Rafael Mejuto-Fernandez
JIJulio Iglesias-Garcia
Julio Iglesias-Garcia
Endoscopic ultrasound (EUS) was first described in 1986, with the aim of overcoming the problems affecting transabdominal ultrasound imaging, mainly problems related to the interposition of gas, and artifacts produced by bone or fat. Now, EUS can be considered as the best method for the analysis of pancreatic diseases, overtaking the diagnostic accuracy of computed tomography and magnetic resonance imaging. However, fundamental B-mode imaging is limited for the diagnosis of solid pancreatic lesions, because most of them are depicted as heterogeneous and hypo-echoic, and it is difficult to differentiate between benign and malignant lesions. Similar to how perfusion patterns obtained by computed tomography or magnetic resonance imaging after injection of contrast agents allow for the characterization of focal lesions, EUS has also recently been introduced to the use of contrast agents for performing contrast-enhanced harmonic EUS (CEH-EUS), which has the capability to distinguish the type of perfusion between lesions and surrounding tissue. CEH-EUS has shown its usefulness for the diagnosis and characterization of solid pancreatic lesions. Moreover, CEH-EUS is also highly accurate for distinguishing non-neoplastic from neoplastic cysts in pancreatic lesions. Another potential role of CEH-EUS is its ability to direct EUS-guided tissue acquisition.

1 May 2020 in Medicine - Programa de Formación Médica Continuada Acreditado
Verified
Journal Article
Closed access
RFR. Mejuto Fernández
R. Mejuto Fernández
NSN. Vallejo Senra
N. Vallejo Senra
ERE. Flores Ríos
E. Flores Ríos
VBV. Mauriz Barreiro
V. Mauriz Barreiro
JDJ.E. Domínguez-Muñoz
J.E. Domínguez-Muñoz

23 June 2022
Verified
Book Chapter
Closed access
PDF file
RFRafael Mejuto Fernandez
Rafael Mejuto Fernandez
MKMarina Kim
Marina Kim
MKMichel Kahaleh
Michel Kahaleh

1 September 2019 in Pancreatology
Verified
Journal Article
Closed access
JIJulio Iglesias-Garcia
Julio Iglesias-Garcia
EME. Martínez Moneo
E. Martínez Moneo
RFR. Mejuto Fernández
R. Mejuto Fernández
NMN. Gendive Martín
N. Gendive Martín
VBV. Mauriz Barreiro
V. Mauriz Barreiro
JMJ.E. Domínguez Muñoz
J.E. Domínguez Muñoz